AI Article Synopsis
- The study examined the effectiveness of ongoing treatment with EGFR tyrosine kinase inhibitors (TKIs) in lung adenocarcinoma patients who have favorable mutations and develop new, less aggressive lesions.
- Out of 102 patients analyzed, those who continued EGFR-TKI therapy had a median overall survival of 791 days, significantly longer than the 529 days for those who stopped treatment.
- Continuous EGFR-TKI treatment did not negatively impact survival, indicating that managing new lesions while maintaining treatment can be beneficial.
Article Abstract
Background: In this study, we investigated the efficacy of continuous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) administration in lung adenocarcinoma patients harboring favorable mutations regarding the progressive disease (PD) status with appearance of indolent new lesions.
Methods: From June 2010 to October 2012, 102 patients with lung adenocarcinoma, harboring favorable EGFR mutations and treated with EGFR-TKI were analyzed. Definite new lesions were detected during EGFR-TKI therapy, even though the primary target tumors were controlled.
Results: Of the 102 patients, 57 continued and 45 discontinued EGFR-TKI therapy. The median overall survival was 529 days for the discontinuation group and 791 days for the continuation group (p = 0.0197). Median survival time after the discontinuation of EGFR-TKI was 181 days and 115 days in the discontinuation and continuation groups, respectively (p = 0.1776), whereas median survival time after the appearance of indolent new lesions was 204 days and 262 days, respectively (p = 0.0237).
Conclusion: Continuous EGFR-TKI administration in favorable EGFR-mutative lung adenocarcinoma patients with controlled primary tumors did not hinder the survival benefit, despite the appearance of new lesions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140297 | PMC |
| http://dx.doi.org/10.1016/j.bj.2015.07.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction to "Olink Proteomics-Based Exploration of Immuno-Oncology-Related Biomarkers Leading to Lung Adenocarcinoma Progression".
J Proteome Res
January 2025
Department of Thoracic Surgery, Ningbo No.2 Hospital, Ningbo, 315010 Zhejiang, China.
Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma.
Pharmacoeconomics
January 2025
Division of Pulmonology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Shengli Road, Tainan, 704, Taiwan.
Background And Objective: Approximately half of lung adenocarcinomas in East Asia harbor epidermal growth factor receptor (EGFR) mutations. EGFR testing followed by tissue-based next-generation sequencing (NGS), upfront tissue-based NGS, and complementary NGS approaches have emerged on the front line to guide personalized therapy. We study the cost effectiveness of exclusionary EGFR testing for Taiwanese patients newly diagnosed with advanced lung adenocarcinoma.
View Article and Find Full Text PDFFAM107A Inhibits the Growth, Invasion and Aerobic Glycolysis of LUAD Cells by Regulating CRYAB/PI3K/AKT.
Biochem Genet
January 2025
Department of Cardiac Function, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430070, Hubei, China.
Lung adenocarcinoma (LUAD) is characterized by its aggressive nature and resistance to treatment. FAM107A is a tumor suppressor gene that has been found to possess inhibitory effects in several cancers, but its role in LUAD remains unclear. This study investigated the role of FAM107A in regulating LUAD cell growth, invasion and aerobic glycolysis and also investigated the potential underlying mechanisms.
View Article and Find Full Text PDFA rare EGFR exon 19 insertion mutation in metastatic lung adenocarcinoma: a favorable response to afatinib.
Anticancer Drugs
February 2025
Department of Medical Oncology, Ankara Bilkent City Hospital, Medical Oncology Clinic.
Epidermal growth factor receptor (EGFR) mutations like the common L858R and exon 19 deletions are well studied, but rarer mutations like exon 19 insertions have received less attention. This case report describes a patient with this uncommon EGFR exon 19 insertion mutation in metastatic lung adenocarcinoma. A 51-year-old male nonsmoker with metastatic lung adenocarcinoma and a rare EGFR exon 19 insertion mutation experienced disease progression on initial carboplatin-pemetrexed chemotherapy.
View Article and Find Full Text PDFIntrathecal methotrexate injection combined treatment of gastric cancer with leptomeningeal metastasis: case report.
Front Oncol
December 2024
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Background: Leptomeningeal metastasis of gastric adenocarcinoma (LM-GC) is a rare and severe complication with a poor prognosis, its prognosis is significantly poorer than liver, lung, and peritoneal metastases. Studies on LM-GC have been limited to clinical case reports. Despite advances in systemic therapies, there is a lack of standardized treatment protocols for LM-GC due to its rarity and the challenges it presents.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!